Item 5. Other Information
Item
5. Other Information . None.
Item
6. Exhibits.
10.1 Assignment
Agreement dated May 1, 2021, between the Company, OntoChem GmbH and MolGenie GmbH.
10.2 Amendment
2 to the Collaboration Agreement between the Company and MolGenie GmbH. (C ertain information has been redacted
in the marked portions of the exhibit.)
31.1 Certification
of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated
June 10, 2021.
31.2 Certification
of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated
June 10, 2021.
32.1 Statement
of Chief Executive Officer, pursuant to Section 1350 of Title 18 of the United States Code,
dated June 10,2021.
32.2 Statement
of Chief Financial Officer, pursuant to Section 1350 of Title 18 of the United States Code,
dated June 10, 2021.
27
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by
the undersigned, thereunto duly authorized.
ANIXA
BIOSCIENCES, INC.
By:
/s/
Dr. Amit Kumar
Dr.
Amit Kumar
Chairman,
President and
Chief
Executive Officer
June
10, 2021
(Principal
Executive Officer)
By:
/s/
Michael J. Catelani
Michael
J. Catelani
Chief
Operating Officer and
Chief
Financial Officer
(Principal
Financial and
June
10, 2021
Accounting
Officer)
28
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.